ERBB2 and breast carcinoma: Although most clinical evidence suggests that lapatinib is particularly effective for HER2-positive breast cancer because it acts by reversible inhibition of the HER2 receptor [19, 20, 22, 23], the antitumor effect of lapatinib in HER2-negative breast cancer continues to be of interest.